Our goal is to find and guide cures for patients diagnosed with rare cancers. We focus on areas of high, unmet need; rare cancer indications with high mortality rates and few therapeutic options beyond resection and radiation.
Under active investigation: adenoid cystic carcinoma, adrenocortical carcinoma, Ewing’s sarcoma, neuroblastoma, and rhabdomyosarcoma. We strive to match each biological target with the optimal platform (small molecule, antibody, targeted nanoparticle). All projects are currently in preclinical phase of testing and collaborators including the National Cancer Institute, University College London, and MIT.
Our criteria for indication selection: